Cervical Laminoplasty Titanium Miniplate System with Bone Plate Implants for Orthopedic Posterior Surgery

Name: Cervical Laminoplasty Titanium Miniplate System with Bone Plate Implants for Orthopedic Posterior Surgery
Brand: Shanghai A-Orth Medical Co., Ltd.
SKU: 2317494625

Shanghai, ChinaShanghai A-Orth Medical Co., Ltd.

US$90.00-120.00

1 Set

Sample price:US$120.00/piece.Request sample

Product profile

Customization

Available

Certification

FDA, QS, ISO, CE

Disinfection

Model NO.

zipper

Application

Posterior Cervical Fixation

Material

Titanium

Transport Package

Carton

Trademark

A-ORTH

Origin

China

HS Code

90211000

Production Capacity

10, 000 PCS/Year

Key features

Diversified Plate System: Covers lamina frame, bone graft, lateral hole, wide-mouth, and door-shaft subtypes.

Structural Support Design: Enlarges spinal canal space and enhances postoperative spinal stability.

Porous Plate Body: Facilitates multi-angle screw fixation to lock lateral mass firmly.

Precision Screw System: Self-drilling and self-tapping screws reduce intraoperative difficulty.

ISO 13485 Certified: Company certified under ISO 9001:2015 and EN ISO 13485:2016 standards.

Customized Packing: Customized packing design service is available for clients.

High Production Capacity: Monthly output reaches 10,000 units with advanced CNC equipment.

Global Export Experience: Products exported to North America, Europe, Asia, Africa, and Latin America.

Company profile

Shanghai A-Orth Medical Co., Ltd.

Shanghai, China

Business Type: Trading CompanyExport Year: 2016-02-01 CertifiedNearest Port: Shanghai PortAverage Response Time: ≤8.15h CertifiedTerms of Payment: T/T, Western Union, Small-amount payment CertifiedInternational Commercial Terms(Incoterms): FOB, CIF

AI-Powered supplier vetting

SummaryShanghai A-Orth Medical Co., Ltd. is a China-based trading company focused on orthopedic implants, spine systems, instruments, and power tools. It reports self-operated import and export rights, began exporting in 2016, and derives 90% of total sales from exports. The supplier lists ISO 9000, ISO 13485, ISO 9001, GMP, and QC 080000 certifications. Reported operational capabilities include more than 10 production lines, 21–30 R&D engineers, 21–30 quality-control staff, specified annual product volumes, broad export-market coverage, and an off-peak lead time within 15 working days. However, the available information does not establish after-sales procedures, customization services, financial reliability, or verified customer case details. The trade record shows one transaction and one associated buyer, which is insufficient for a broad customer-track-record assessment.

Supplier typeThe supplier is explicitly identified as a trading company, with its business focused on health and medicine and its product range covering trauma implants, spine implants, instruments, and power tools. Its description indicates involvement in the sale of orthopedic and other medical products, while the production-related data suggests access to manufacturing capabilities.

CertificationsThe supplier lists ISO 9000, ISO 13485, ISO 9001, GMP, and QC 080000 certifications. ISO 13485 and GMP are directly relevant to medical-device quality and manufacturing controls, although the provided information does not include certificate validity periods or scope details.

R&D capabilityThe supplier reports 21–30 R&D engineers and describes strong technical capability, with products developed in conjunction with clinical experience. Its orthopedic portfolio includes specialized products such as interbody fusion cages, pedicle screws, locking systems, and power tools, providing evidence of product-development activity but not proof of proprietary innovation or patents.

Production capacityThe supplier reports more than 10 production lines, 21–30 quality-control staff, and defined annual outputs including 300,000 titanium screws, 50,000 locking plates, 50,000 interlocking nails, 10,000 interbody fusion cages, and 5,000 instrument sets. It also reports an off-peak lead time within 15 working days, supporting a positive assessment of stated production capacity and fulfillment readiness.